FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996408040> ?p ?o ?g. }

• W1996408040 endingPage "52" @default.
• W1996408040 startingPage "45" @default.
• W1996408040 abstract "Objectives: Our previous studies have shown that, contrary to many other human pancreatic adenocarcinoma cell lines, AsPC1 cells are resistant to the apoptotic effect of the tumor necrosis factor-related apoptosis-inducing ligand, also called Apo2L (TRAIL/Apo2L). In our in vitro studies, the combination of TRAIL/Apo2L and protein synthesis inhibitor, genistein, but not genistein alone, was, however, effective in inducing apoptosis in AsPC1 cells. In the present study, we examined the effect of TRAIL/Apo2L with genistein on the growth of AsPC1 cells in vitro and in vivo. Methods: Mice with orthotopically transplanted AsPC1 cells were treated either with TRAIL/Apo2L, Genistein (Gen) or a combination of both (TRAIL/Apo2L + Gen) for 14 days. After 14 days, the size and weight of the tumors were registered and the apoptosis of the tumor cells were determined by the TUNEL method. In vitro, the effect of combination treatment on cytotoxicity was assessed by MTT assay and apoptosis was assessed by DAPI staining. FADD, caspase 3, and PARP proteins were determined by Western blot. Results: No toxic side effects were observed in either group. The tumor volume was significantly smaller and the apoptotic ratio was higher in the TRAIL + Gen group than in the other 2 groups. The apoptotic effect was associated with the caspase-3 activation. Z-VAD-FMK partially inhibited apoptosis by TRAIL + Gen. Conclusions: These results indicate that the combination of TRAIL/Apo2L with genistein presents a promising therapeutic approach for the treatment of pancreatic cancer. Further detail investigations are needed, however, to verify the mechanisms of this combination therapy." @default.
• W1996408040 created "2016-06-24" @default.
• W1996408040 creator A5002872975 @default.
• W1996408040 creator A5006400723 @default.
• W1996408040 creator A5009736037 @default.
• W1996408040 creator A5031135696 @default.
• W1996408040 creator A5037138840 @default.
• W1996408040 creator A5040569943 @default.
• W1996408040 creator A5047590273 @default.
• W1996408040 creator A5064999652 @default.
• W1996408040 date "2004-07-01" @default.
• W1996408040 modified "2023-10-18" @default.
• W1996408040 title "The Combination of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL/Apo2L) and Genistein Is Effective in Inhibiting Pancreatic Cancer Growth" @default.
• W1996408040 cites W1484817497 @default.
• W1996408040 cites W1656644300 @default.
• W1996408040 cites W1946359192 @default.
• W1996408040 cites W1972472953 @default.
• W1996408040 cites W1972779778 @default.
• W1996408040 cites W1973848893 @default.
• W1996408040 cites W1974503298 @default.
• W1996408040 cites W1976128207 @default.
• W1996408040 cites W1989345460 @default.
• W1996408040 cites W1990651658 @default.
• W1996408040 cites W2004457956 @default.
• W1996408040 cites W2007278554 @default.
• W1996408040 cites W2011821957 @default.
• W1996408040 cites W2030573603 @default.
• W1996408040 cites W2039616505 @default.
• W1996408040 cites W2049312704 @default.
• W1996408040 cites W2056217426 @default.
• W1996408040 cites W2077098724 @default.
• W1996408040 cites W2085233944 @default.
• W1996408040 cites W2090782347 @default.
• W1996408040 cites W2092508425 @default.
• W1996408040 cites W2096428903 @default.
• W1996408040 cites W2097767970 @default.
• W1996408040 cites W2116393840 @default.
• W1996408040 cites W2123504758 @default.
• W1996408040 cites W2130988210 @default.
• W1996408040 cites W2150881991 @default.
• W1996408040 cites W2163958696 @default.
• W1996408040 cites W2180159320 @default.
• W1996408040 cites W2315436341 @default.
• W1996408040 cites W2319486658 @default.
• W1996408040 cites W2330709458 @default.
• W1996408040 cites W2331185281 @default.
• W1996408040 cites W3188033896 @default.
• W1996408040 cites W4241578751 @default.
• W1996408040 doi "https://doi.org/10.1097/00006676-200407000-00055" @default.
• W1996408040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15211111" @default.
• W1996408040 hasPublicationYear "2004" @default.
• W1996408040 type Work @default.
• W1996408040 sameAs 1996408040 @default.
• W1996408040 citedByCount "33" @default.
• W1996408040 countsByYear W19964080402013 @default.
• W1996408040 countsByYear W19964080402014 @default.
• W1996408040 countsByYear W19964080402015 @default.
• W1996408040 countsByYear W19964080402016 @default.
• W1996408040 countsByYear W19964080402018 @default.
• W1996408040 countsByYear W19964080402022 @default.
• W1996408040 countsByYear W19964080402023 @default.
• W1996408040 crossrefType "journal-article" @default.
• W1996408040 hasAuthorship W1996408040A5002872975 @default.
• W1996408040 hasAuthorship W1996408040A5006400723 @default.
• W1996408040 hasAuthorship W1996408040A5009736037 @default.
• W1996408040 hasAuthorship W1996408040A5031135696 @default.
• W1996408040 hasAuthorship W1996408040A5037138840 @default.
• W1996408040 hasAuthorship W1996408040A5040569943 @default.
• W1996408040 hasAuthorship W1996408040A5047590273 @default.
• W1996408040 hasAuthorship W1996408040A5064999652 @default.
• W1996408040 hasConcept C121608353 @default.
• W1996408040 hasConcept C126322002 @default.
• W1996408040 hasConcept C17991360 @default.
• W1996408040 hasConcept C185592680 @default.
• W1996408040 hasConcept C190283241 @default.
• W1996408040 hasConcept C196795494 @default.
• W1996408040 hasConcept C2776055636 @default.
• W1996408040 hasConcept C2777527632 @default.
• W1996408040 hasConcept C2778298627 @default.
• W1996408040 hasConcept C2780210213 @default.
• W1996408040 hasConcept C2780783641 @default.
• W1996408040 hasConcept C31573885 @default.
• W1996408040 hasConcept C502942594 @default.
• W1996408040 hasConcept C55493867 @default.
• W1996408040 hasConcept C71924100 @default.
• W1996408040 hasConcept C98424977 @default.
• W1996408040 hasConceptScore W1996408040C121608353 @default.
• W1996408040 hasConceptScore W1996408040C126322002 @default.
• W1996408040 hasConceptScore W1996408040C17991360 @default.
• W1996408040 hasConceptScore W1996408040C185592680 @default.
• W1996408040 hasConceptScore W1996408040C190283241 @default.
• W1996408040 hasConceptScore W1996408040C196795494 @default.
• W1996408040 hasConceptScore W1996408040C2776055636 @default.
• W1996408040 hasConceptScore W1996408040C2777527632 @default.
• W1996408040 hasConceptScore W1996408040C2778298627 @default.
• W1996408040 hasConceptScore W1996408040C2780210213 @default.
• W1996408040 hasConceptScore W1996408040C2780783641 @default.
• W1996408040 hasConceptScore W1996408040C31573885 @default.

• next